摘要
目的探讨原发性乳腺弥漫性大B细胞淋巴瘤(primary breast diffuse large B-cell lymphoma,PB-DLBCL)的临床病理特征、诊断、鉴别诊断、治疗及预后。方法回顾性分析4例PB-DLBCL患者的临床表现、病理学特征、免疫表型特征,并复习相关文献。结果4例均为女性患者,中位年龄58.5岁,范围为45~69岁。病变部位左侧3例,右侧1例。镜下乳腺正常结构被破坏,均未见包膜,在残存数量不等的乳腺导管或小叶之间有大量弥漫浸润生长的中等偏大的异型淋巴样细胞,瘤细胞浸润脂肪组织;未见淋巴上皮病变,以中心母细胞样细胞(3例)和免疫母细胞样细胞(1例)为主;免疫表型提示4例均为非生发中心B细胞样(non-GCB)型DLBCL,瘤细胞均表达LCA、CD20、CD79a和MUM-1,Ki67增殖指数50%~80%。病例随访时间截止至2017年12月,随访期内有1例复发,13个月后死亡,1例健在,已存活66个月,另2例失访。结论PB-DLBCL极为少见,主要见于女性,细胞起源分型大部分为non-GCB型,临床常易误诊为乳腺癌,该病确诊需依靠病理活检及免疫表型,治疗暂不明确,推荐R-CHOP/CHOP化疗联合放疗等的综合治疗方案。
Abstract Objective To discuss the clinical pathological features,diagnosis and differential diagnosis,therapy and prognosis of primary breast diffuse large B-cell lymphoma(PB-DLBCL).Methods The clinical manifestations,pathological features,immunophenotypic characteristics of 4 cases of PB-DLBCL were retrospectively reviewed,and related literatures were reviewed.Results All of the 4 patients were women,aged 45 to 69 years,with the median 58.5 years.There were 3 cases of lesions involving the left breast and 1 case of the right breast.Microscopic observation showed that the normal structure of the mammary gland was destroyed,and no capsule was seen.There was a large number of large-to medium-sized heterotypic lymphoid cells which characterized as diffuse infiltration between the remaining ducts or lobules of mammary gland.Tumor cells infiltrated adipose tissue,mainly as central blast-like cells(3 cases)and immunoblast-like cells(1 case).No lymphatic epithelial lesions were observed.The immunophenotype showed 4 cases were non-GCB type.Immunostaining showed that the neoplastic cells were LCA,CD20,CD79a and MUM-1 positive.Ki67 index were from 50% to 80%.The follow-up time of these cases was until Dec.2017.There was one recurrence during the follow-up period.The patient died 13 months later.One patient was alive and had survived for 66 months.Two patients were lost to follow-up.Conclusions PB-DLBCL is extremely rare,mainly found in women.Most of the cell origin types are non-GCB type,which is often misdiagnosed as breast cancer.The diagnosis of PB-DLBCL is confirmed by pathological biopsy and immunohistochemical markers.The treatment is not clear,and a comprehensive treatment plan such as R-CHOP/CHOP chemotherapy combined with radiotherapy is recommended.
作者
谢永辉
柯晓康
袁静萍
Xie Yonghui;Ke Xiaokang;Yuan Jingping(Department of Pathology,Central Hospital of Wuhan,Wuhan 430014,China;Department of Pathology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《中华内分泌外科杂志》
CAS
2019年第1期54-58,共5页
Chinese Journal of Endocrine Surgery
基金
武汉市科技计划项目(2017060201010172)
武汉大学人民医院引导基金(RMYD2018M27)。
